Core Viewpoint - BOOST Pharma has successfully raised SEK 34 million through a tranched convertible loan from Sound Bioventures to support the clinical development of BT-101, a stem cell-based therapy for Osteogenesis imperfecta (OI) [1][3]. Group 1: Company Overview - BOOST Pharma is a clinical-stage biopharmaceutical company focused on developing BT-101, a novel mesenchymal stem cell therapy aimed at infants with Osteogenesis imperfecta, a condition that leads to fragile bones and frequent fractures [2]. - The treatment targets the genetic cause of OI and aims to reduce fracture frequency in affected children from an early age, potentially providing significant treatment advantages during the critical early years of life [2]. Group 2: Investment and Financial Position - The investment from Sound Bioventures, along with recent financing in which Karolinska Development participated, will enable BOOST Pharma to accelerate its clinical development program and work towards offering the first disease-modifying treatment for OI [3]. - Karolinska Development holds a 14 percent ownership stake in BOOST Pharma, indicating a strong financial position that supports the accelerated development of BT-101 [4]. Group 3: Company Strategy and Goals - Karolinska Development aims to identify and invest in breakthrough medical innovations in the Nordic region, focusing on companies that can advance these innovations into commercial products that improve patient lives while providing returns to shareholders [5][6]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by experienced management teams and a global network of investors [7].